Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

Fig. 3

Overall survival (OS) for pembrolizumab with or without chemotherapy. Kaplan–Meier curves illustrating the OS of patients with large-cell carcinoma (LCC) (A, C) or large-cell neuroendocrine carcinoma (LCNEC) (B, D) who received pembrolizumab with chemotherapy as first-line therapy (A, B) or pembrolizumab with or without chemotherapy as second-line or later-line therapy (C, D). The OS was computed from the initiation of pembrolizumab-containing regimen until death or last follow-up. Dashed lines correspond to the 95% lower and upper confidence intervals. Tick marks indicate the number of censored cases per time point. The risk table below shows the number of cases per time point

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us